Show simple item record

dc.contributor.authorD'Erme, A.M.*
dc.contributor.authorWilsmann-Theis, D.*
dc.contributor.authorWagenpfeil, J.*
dc.contributor.authorHölzel, M.*
dc.contributor.authorSternberg, S.*
dc.contributor.authorWittmann, Miriam*
dc.contributor.authorPeters, B.*
dc.contributor.authorBosio, A.*
dc.contributor.authorBieber, T.*
dc.contributor.authorWenzel, J.*
dc.date.accessioned2015-10-13T14:21:31Z
dc.date.available2015-10-13T14:21:31Z
dc.date.issued2015-01
dc.identifier.citationD'Erme AM, Wilsmann-Theis D, Wagenpfeil J et al (2015) IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions. Journal of Investigative Dermatology. 135(4): 1025-32.en_US
dc.identifier.urihttp://hdl.handle.net/10454/7426
dc.descriptionNoen_US
dc.description.abstractIn recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not only psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/tumor necrosis factor-α (TNFα)-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses, IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, because of its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.en_US
dc.language.isoenen_US
dc.subjectPsoriasisen_US
dc.subjectSkin lesions
dc.subjectBiomarkers
dc.subjectInflamatory skin diseases
dc.titleIL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesionsen_US
dc.status.refereedYesen_US
dc.typeArticleen_US
dc.type.versionNo full-text in the repositoryen_US
dc.identifier.doihttps://doi.org/10.1038/jid.2014.532


This item appears in the following Collection(s)

Show simple item record